Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R
-
- Matteo G. Della Porta
- Department of Hematology Oncology, Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy;
-
- Emilio Paolo Alessandrino
- Department of Hematology Oncology, Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy;
-
- Andrea Bacigalupo
- Department of Hematology, San Martino Hospital, Genova, Italy;
-
- Maria Teresa van Lint
- Department of Hematology, San Martino Hospital, Genova, Italy;
-
- Luca Malcovati
- Department of Hematology Oncology, Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy;
-
- Cristiana Pascutto
- Department of Hematology Oncology, Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy;
-
- Michele Falda
- Department of Hematology, San Giovanni Battista Hospital, Turin, Italy;
-
- Massimo Bernardi
- Hematology and Bone Marrow Transplant Unit, Department of Oncology, San Raffaele Scientific Institute, Milan, Italy;
-
- Francesco Onida
- Hematology and Bone Marrow Transplantation Center, Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico Ospedale Maggiore Policlinico and University of Milan, Milan, Italy;
-
- Stefano Guidi
- Division of Hematology and Bone Marrow Transplantation, Azienda Ospedaliera Universitaria Careggi, Florence, Italy;
-
- Anna Paola Iori
- Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy;
-
- Raffaella Cerretti
- Rome Transplant Network, Department of Hematology, Stem Cell Transplant Unit, Policlinico Tor Vergata, Rome, Italy;
-
- Paola Marenco
- Department of Hematology Oncology, Ospedale Niguarda Ca' Granda, Milan, Italy;
-
- Pietro Pioltelli
- Division of Hematology and Transplant Unit, Ospedale San Gerardo, Monza, Italy;
-
- Emanuele Angelucci
- Hematology and Bone Marrow Transplantation Unit, Ospedale Oncologico di Riferimento Regionale Armando Businco, Cagliari, Italy; and
-
- Rosi Oneto
- Department of Hematology, San Martino Hospital, Genova, Italy;
-
- Francesco Ripamonti
- Department of Hematology Oncology, Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy;
-
- Paolo Bernasconi
- Department of Hematology Oncology, Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy;
-
- Alberto Bosi
- Division of Hematology and Bone Marrow Transplantation, Azienda Ospedaliera Universitaria Careggi, Florence, Italy;
-
- Mario Cazzola
- Department of Hematology Oncology, Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy;
-
- Alessandro Rambaldi
- Hematology and Bone Marrow Transplant Units of Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
抄録
<jats:title>Key Points</jats:title> <jats:p>Disease relapse is a common cause of failure of allogeneic hematopoietic stem cell transplantation in patients with advanced MDS. High IPSS-R prognostic risk category and monosomal karyotype are independent predictors of relapse after allogeneic transplantation in MDS.</jats:p>
収録刊行物
-
- Blood
-
Blood 123 (15), 2333-2342, 2014-04-10
American Society of Hematology